FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate) submitted by Wyeth/Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• PRISTIQ EXTENDED-RELEASE (Desvenlafaxine succinate)

Snippet

SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)